WO2022060204A1 - 바실러스 효소군 이용 생물전환된 기능성 약콩분말을 유효성분으로 포함하는 조성물 및 이의 용도 - Google Patents
바실러스 효소군 이용 생물전환된 기능성 약콩분말을 유효성분으로 포함하는 조성물 및 이의 용도 Download PDFInfo
- Publication number
- WO2022060204A1 WO2022060204A1 PCT/KR2021/012972 KR2021012972W WO2022060204A1 WO 2022060204 A1 WO2022060204 A1 WO 2022060204A1 KR 2021012972 W KR2021012972 W KR 2021012972W WO 2022060204 A1 WO2022060204 A1 WO 2022060204A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bacillus polyfermenticus
- strain
- bioconversion
- kmu01
- kctc
- Prior art date
Links
- 239000000843 powder Substances 0.000 title claims abstract description 53
- 235000010469 Glycine max Nutrition 0.000 title claims abstract description 49
- 244000068988 Glycine max Species 0.000 title claims abstract description 49
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 239000004480 active ingredient Substances 0.000 title claims abstract description 13
- 102000004190 Enzymes Human genes 0.000 title abstract description 45
- 108090000790 Enzymes Proteins 0.000 title abstract description 45
- 241000193830 Bacillus <bacterium> Species 0.000 title 1
- 241001226430 Bacillus polyfermenticus Species 0.000 claims abstract description 48
- 229940104704 bacillus polyfermenticus Drugs 0.000 claims abstract description 47
- 230000000694 effects Effects 0.000 claims abstract description 37
- 235000013322 soy milk Nutrition 0.000 claims abstract description 35
- 230000003542 behavioural effect Effects 0.000 claims abstract description 24
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 9
- 239000001963 growth medium Substances 0.000 claims description 19
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 16
- 108091005804 Peptidases Proteins 0.000 claims description 15
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000004365 Protease Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 230000036541 health Effects 0.000 claims description 10
- 239000002609 medium Substances 0.000 claims description 10
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 claims description 9
- 235000013376 functional food Nutrition 0.000 claims description 9
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 claims description 9
- 229940086319 nattokinase Drugs 0.000 claims description 9
- 108010073682 nattokinase Proteins 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 abstract description 10
- 230000006872 improvement Effects 0.000 abstract description 10
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 9
- 238000000855 fermentation Methods 0.000 abstract description 6
- 230000004151 fermentation Effects 0.000 abstract description 6
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 5
- 102000004317 Lyases Human genes 0.000 abstract 1
- 108090000856 Lyases Proteins 0.000 abstract 1
- 102000056222 Peptide Synthases Human genes 0.000 abstract 1
- 108700018928 Peptide Synthases Proteins 0.000 abstract 1
- 229940088598 enzyme Drugs 0.000 description 43
- 108090000623 proteins and genes Proteins 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 241000255588 Tephritidae Species 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 208000035475 disorder Diseases 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- 102000035195 Peptidases Human genes 0.000 description 14
- 230000009194 climbing Effects 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 235000019419 proteases Nutrition 0.000 description 10
- 235000013305 food Nutrition 0.000 description 9
- -1 potatoes Natural products 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 239000001974 tryptic soy broth Substances 0.000 description 8
- 108010050327 trypticase-soy broth Proteins 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 7
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 108010073771 Soybean Proteins Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 230000029251 gravitaxis Effects 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 4
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000000593 degrading effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 244000013123 dwarf bean Species 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 235000021107 fermented food Nutrition 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 229940014259 gelatin Drugs 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000021374 legumes Nutrition 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 230000037230 mobility Effects 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000004622 sleep time Effects 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000002537 thrombolytic effect Effects 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010059892 Cellulase Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 102000018389 Exopeptidases Human genes 0.000 description 2
- 108010091443 Exopeptidases Proteins 0.000 description 2
- 108010056771 Glucosidases Proteins 0.000 description 2
- 102000004366 Glucosidases Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 150000005693 branched-chain amino acids Chemical class 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 229940106157 cellulase Drugs 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 235000002949 phytic acid Nutrition 0.000 description 2
- 239000000467 phytic acid Substances 0.000 description 2
- 229940068041 phytic acid Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229940001941 soy protein Drugs 0.000 description 2
- 235000019710 soybean protein Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 244000066764 Ailanthus triphysa Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 101001074429 Bacillus subtilis (strain 168) Polyketide biosynthesis acyltransferase homolog PksD Proteins 0.000 description 1
- 101000936617 Bacillus velezensis (strain DSM 23117 / BGSC 10A6 / FZB42) Polyketide biosynthesis acyltransferase homolog BaeD Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 101100455752 Caenorhabditis elegans lys-3 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 108700013639 Drosophila w Proteins 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 102100030569 Nuclear receptor corepressor 2 Human genes 0.000 description 1
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108090000279 Peptidyltransferases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000005904 anticancer immunity Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 108010041102 azocasein Proteins 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000021332 kidney beans Nutrition 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000011269 tar Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 108010030159 thrombin receptor peptide 14 Proteins 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/02—Aminoacyltransferases (2.3.2)
- C12Y203/02002—Gamma-glutamyltransferase (2.3.2.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21062—Subtilisin (3.4.21.62)
Definitions
- the present invention relates to a composition comprising green soybean bioconversion powder as an active ingredient and a use thereof, and more particularly, to whole soymilk with an enzyme solution derived from a Bacillus polyfermenticus strain, whereby various physiologically active functions are improved. It relates to a composition comprising the medicinal soybean bioconversion powder.
- Exercise performance is the ability to perform exercise using muscle strength, and when exercise performance is reduced or imbalanced, abnormal movement or gait occurs, impairing normal movement and making posture poor.
- the amount of exercise is insufficient, which can cause problems such as decreased physical strength, obesity, hyperlipidemia, and high blood pressure. Therefore, in order to lead a normal healthy life, it is necessary to improve exercise performance.
- soybeans contain protein, fat, and various functional ingredients that are good for the body. As an ideal food with excellent nutritional value, soybeans are very important and essential food for dietary life. In addition, in recent years, as new physiological functions such as anti-cancer properties and immunity enhancement are more known, the nutritional value of soybeans as a functional food is increasing day by day.
- Soy milk one of the representative processed foods of soybeans, is a representative processed soybean product that increases the protein utilization of soybeans. It is rich in soy protein, essential amino acids and essential fatty acids, and contains minerals such as iron, phosphorus, potassium, It is known as a functional nutritional beverage because it contains a large amount of physiologically active substances, which are functional ingredients such as phytic acid and phytic acid.
- soymilk is treated with proteolytic enzymes to decompose soy protein to promote digestion and absorption, as well as to enhance functionality by producing peptides with physiological activities such as blood pressure enhancement, calcium absorption promotion, anti-allergy and blood cholesterol lowering action. Research to improve it is being conducted. However, the effect of improving exercise performance is still unknown.
- an object of the present invention is to provide a medicinal bean bioconversion powder with improved functionality and a method for preparing the same, and various degrading enzymes and peptide synthetase derived from Bacillus polyfermenticus strains.
- the weak soybean bioconversion powder is effective. It is to provide a composition for improving behavioral disorders containing as a component.
- the present invention provides a composition for bioconversion comprising a Bacillus polyfermenticus KMU01 (Accession Number: KCTC 11751BP) strain, its culture medium, its fermented product, or a mixture thereof.
- KMU01 Bacillus polyfermenticus KMU01 (Accession Number: KCTC 11751BP) strain, its culture medium, its fermented product, or a mixture thereof.
- Bacillus polyfermenticus Bacillus polyfermenticus
- KMU01 Bacillus polyfermenticus
- its culture medium Bacillus polyfermenticus
- its fermented product or a mixture thereof to whole soy milk
- the present invention is a behavioral disorder comprising Bacillus polyfermenticus KMU01 (Accession No.: KCTC 11751BP) strain, its culture medium, its fermented product, or whole soymilk fermented as an active ingredient, as an active ingredient It provides a pharmaceutical composition for the prevention or treatment of.
- the present invention is a behavioral disorder comprising Bacillus polyfermenticus KMU01 (Accession No.: KCTC 11751BP) strain, its culture medium, its fermented product, or whole soymilk fermented as an active ingredient, as an active ingredient It provides a health functional food composition for the prevention or improvement of.
- low molecular weight functional amino acids and peptides are formed by treating whole soymilk with a fermentation broth mixed with various degrading enzymes and peptide synthesizing enzymes derived from Bacillus polyfermenticus strains.
- the conversion powder exhibits functional effects such as antioxidant activity and improvement of behavioral disorders, it is possible to provide a medicinal bean bioconversion powder and a manufacturing method thereof.
- Bacillus polyfermenticus Bacillus polyfermenticus
- the present invention provides a composition for bioconversion comprising a Bacillus polyfermenticus KMU01 (Accession Number: KCTC 11751BP) strain, its culture medium, its fermented product, or a mixture thereof.
- KMU01 Bacillus polyfermenticus KMU01 (Accession Number: KCTC 11751BP) strain, its culture medium, its fermented product, or a mixture thereof.
- the bioconversion is a technology for converting an existing material (substrate) using a biological reaction of a microorganism or an enzyme produced by the microorganism.
- the bioconversion is Bacillus polyfermenticus KMU01 (Accession No.: KCTC 11751BP ) refers to the transformation of soybeans or weak soybeans (substrate) by using the enzyme group, which is a culture supernatant containing various enzymes produced by the strain, and the product made through the above bioconversion was called weak soybean bioconversion powder.
- Bacillus polyfermenticus Bacillus polyfermenticus
- KMU01 Bacillus polyfermenticus
- KCTC 11751BP Bacillus amyloliquefaciens Kimchi to the Center for Biological Resources (KCTC) on August 25, 2010, After that, as the species name of the clear strain was revealed to be Bacillus polyfermenticus , on June 27, 2018, the species name was changed to Bacillus polyfermenticus KMU01.
- the culture medium may be an artificial medium culturing the Bacillus polyfermenticus KMU01 (Accession No.: KCTC 11751BP) strain, and the fermented product is Bacillus polyfermenticus KMU01 (Accession No.: KCTC 11751BP) ) may be a natural medium fermented using the strain.
- the artificial medium may be a commercially prepared synthetic medium capable of culturing Bacillus polyfermenticus or bacteria, for example, TBS (Tryptic Soy Broth), TSB (Tryptic Soy Broth) NB (Nutrient Broth) , and LB (Luria-Bertani broth) may be, but is not limited thereto.
- TBS Traptic Soy Broth
- TSB Traptic Soy Broth
- NB Nutrient Broth
- LB Lia-Bertani broth
- the natural medium means a natural product that can be fermented with bacteria, and may be a medium using natural products such as potatoes, tomatoes, and milk, but is not limited thereto.
- the culture medium and the fermented product may exhibit the activity of protease, Gamma-glutamyltransferase (GGT), and Nattokinase.
- GTT Gamma-glutamyltransferase
- Nattokinase Nattokinase
- the protease is an enzyme that hydrolyzes peptide bonds between amino acids constituting a protein as a protease, and in the case of some proteolytic enzymes, an exopeptidase that cuts the amino terminus or carboxyl terminus of a protein. (exopeptidase), and in some cases endopeptidase (eg, trypsin, chemotrypsin, pepsin, papain, elastase) that cuts in the middle of a protein.
- exopeptidase eg, trypsin, chemotrypsin, pepsin, papain, elastase
- the GGT (Gamma-glutamyltransferase, gamma-glutamyl transferase) is an enzyme that transfers the glutamyl group of the gamma-glutamyl compound to an appropriate receptor (amine), and is a type of transacylase.
- the Nattokinase is a thrombolytic enzyme produced while Bacillus natto ingests and grows soybean nutrients when fermenting soybeans, and contains vitamin B group and a large amount of antioxidant enzymes.
- Bacillus polyfermenticus Bacillus polyfermenticus
- KMU01 Bacillus polyfermenticus
- its culture medium Bacillus polyfermenticus
- its fermented product or a mixture thereof to whole soy milk
- the yak bean bioconversion powder refers to a powder form of a product produced by cutting or decomposing carbohydrates and proteins contained in yak beans by reacting yak beans, which are fruits of perennial tendrils of the legume family, with microorganisms or enzymes produced by microorganisms, Specifically, the yak bean bioconversion powder is a product produced by converting yak beans using an enzyme group that is a culture supernatant containing various enzymes produced by the Bacillus polyfermenticus KMU01 (Accession No.: KCTC 11751BP) strain. means the powder of
- the medicinal beans refer to fruits of legumes such as soybeans, white beans, seoritae, kidney beans, and peas, and are not limited to the types of fruits of the legumes.
- the Bacillus polyfermenticus KMU01 (Accession No.: KCTC 11751BP) strain, its culture medium, its fermented product, or a mixture thereof is 3% (v/v) to 7% (v/v) in whole soy milk It may be treated at a concentration, preferably at a concentration of 5% (v/v).
- the Bacillus polyfermenticus KMU01 (Accession No.: KCTC 11751BP) strain, its culture medium, its fermented product, or a mixture thereof can be treated at 35° C. to 40° C. for 3 hours to 5 hours, preferably Preferably, it can be treated at 37°C for 4 hours.
- the medicinal bean bioconversion powder may exhibit antioxidant activity.
- the present invention is a behavioral disorder comprising Bacillus polyfermenticus KMU01 (Accession No.: KCTC 11751BP) strain, its culture medium, its fermented product, or whole soymilk fermented as an active ingredient, as an active ingredient It provides a pharmaceutical composition for the prevention or treatment of.
- the behavioral disorder is a kind of disease such as reduced mobility and reduced sleep time, which is caused by excessive death and lack of dopamine, such as movement disorders, cognitive dysfunction, Parkinson's disease, eating disorders, attention deficit disorder, sleep disorders, and the like.
- the pharmaceutical composition of the present invention may be prepared in unit dose form by formulating using a pharmaceutically acceptable carrier according to a method that can be easily carried out by a person of ordinary skill in the art to which the present invention pertains, or in multiple doses. It can be prepared by introducing into a container.
- the pharmaceutically acceptable carriers are those commonly used in formulation, and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methyl hydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like.
- the pharmaceutical composition of the present invention may further include a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, and the like, in addition to the above components.
- the content of the additive included in the pharmaceutical composition is not particularly limited and may be appropriately adjusted within the content range used for conventional formulation.
- the pharmaceutical composition is an aqueous solution, a suspension, an injectable formulation such as an emulsion, a pill, a capsule, a granule, a tablet, a cream, a gel, a patch, a spray, an ointment, a warning agent, a lotion, a liniment agent, a pasta agent, and a cataplasma It may be formulated in the form of one or more external preparations selected from the group consisting of agents.
- an injectable formulation such as an emulsion, a pill, a capsule, a granule, a tablet, a cream, a gel, a patch, a spray, an ointment, a warning agent, a lotion, a liniment agent, a pasta agent, and a cataplasma It may be formulated in the form of one or more external preparations selected from the group consisting of agents.
- the pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier and diluent for formulation.
- the pharmaceutically acceptable carriers and diluents include starch, sugar, and excipients such as mannitol, fillers and extenders such as calcium phosphate, cellulose derivatives such as carboxymethyl cellulose, hydroxypropyl cellulose, gelatin, alginate, and polyvinyl blood binders such as rolidone, lubricants such as talc, calcium stearate, hydrogenated castor oil and polyethylene glycol, disintegrants such as povidone and crospovidone, surfactants such as polysorbates, cetyl alcohol, and glycerol does not
- the pharmaceutically acceptable carrier and diluent may be biologically and physiologically compatible with the subject. Examples of diluents include, but are not limited to, saline, aqueous buffers, solvents, and/or dispersion media.
- the pharmaceutical composition of the present invention may be administered orally or parenterally (eg, intravenously, subcutaneously, intraperitoneally or topically) according to a desired method.
- parenterally eg, intravenously, subcutaneously, intraperitoneally or topically
- it may be formulated as tablets, troches, lozenges, aqueous suspensions, oily suspensions, prepared powders, granules, emulsions, hard capsules, soft capsules, syrups or elixirs, and the like.
- parenteral administration it may be formulated as an injection, suppository, powder for respiratory inhalation, aerosol for spray, ointment, powder for application, oil, cream, etc.
- the dosage of the pharmaceutical composition of the present invention depends on the patient's condition and weight, age, sex, health condition, dietary constitution specificity, the nature of the preparation, the degree of disease, the administration time of the composition, administration method, administration period or interval, excretion rate , and the range may vary depending on the drug form, and may be appropriately selected by those skilled in the art. For example, it may be in the range of about 0.1 to 10,000 mg/kg, but is not limited now, and may be administered in divided doses from once to several times a day.
- the pharmaceutical composition may be administered orally or parenterally (eg, intravenously, subcutaneously, intraperitoneally or topically) according to a desired method.
- the pharmaceutically effective amount and effective dosage of the pharmaceutical composition of the present invention may vary depending on the formulation method, administration method, administration time and/or route of administration of the pharmaceutical composition, and those of ordinary skill in the art It is possible to easily determine and prescribe an effective dosage for treatment.
- Administration of the pharmaceutical composition of the present invention may be administered once a day, may be administered divided into several times.
- the present invention is a behavioral disorder comprising Bacillus polyfermenticus KMU01 (Accession No.: KCTC 11751BP) strain, its culture medium, its fermented product, or whole soymilk fermented as an active ingredient, as an active ingredient It provides a health functional food composition for the prevention or improvement of.
- the present invention can be generally used as a commonly used food product.
- the food composition of the present invention can be used as a health functional food.
- health functional food means a food manufactured and processed using raw materials or ingredients useful for the human body in accordance with the Health Functional Food Act, and "functionality” refers to the structure and function of the human body. It refers to ingestion for the purpose of obtaining useful effects for health purposes such as regulating nutrients or physiological effects.
- the food composition of the present invention may contain conventional food additives, and the suitability as the "food additive” is determined according to the general rules and general test methods of food additives approved by the Ministry of Food and Drug Safety, unless otherwise specified. It is judged according to the standards and standards related to the item.
- Food Additives Code include, for example, chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid; Mixed preparations such as sodium L-glutamate preparation, noodle-added alkali agent, preservative agent, and tar color agent can be mentioned.
- the food composition of the present invention may be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, and the like.
- hard capsules can be prepared by mixing and filling the composition according to the present invention with additives such as excipients in conventional hard capsules
- the soft capsule is the composition of the composition according to the present invention. It can be manufactured by mixing with additives such as excipients and filling in capsule bases such as gelatin.
- the soft capsule formulation may contain a plasticizer such as glycerin or sorbitol, a colorant, a preservative, and the like, if necessary.
- excipients binders, disintegrants, lubricants, flavoring agents, and the like are described in documents known in the art and include those having the same or similar functions.
- type of food is not particularly limited, and includes all health functional foods in the ordinary sense.
- prevention refers to any act of inhibiting or delaying a disease by administering the composition according to the present invention.
- treatment refers to any action that improves or beneficially changes the symptoms of a disease by administration of the composition according to the present invention.
- improvement refers to any action that improves the bad state of a disease by administering or ingesting the composition of the present invention to an individual.
- Example 1 Evaluation of various enzyme activities derived from fermented food microorganisms
- protease GGT (Gamma-glutamyltransferase, gamma-glutamyl transferase), and nattokinase were evaluated.
- the fermentation strain was inoculated in 50 mL of tryptic soy broth (TSB) medium and cultured at 37° C. for 24 hours, and the supernatant of the culture was collected and centrifuged at 8,000 rpm for 20 minutes. Each enzyme activity was evaluated using the centrifuged supernatant of the culture medium.
- TTB tryptic soy broth
- protease activity 0.1 ml of 0.5% azocasein solution and 0.1 ml of crude enzyme solution as a substrate were put into an Eppendorf tube, and after reacting at 37° C. in a constant temperature water bath for 1 hour, 0.4 ml of 10% trichloroacetic acid solution was added. was added to stop the reaction. The reaction solution was centrifuged at 13,000 rpm for 5 minutes to recover the supernatant, and then to 0.6 ml of the supernatant, 0.6 ml of 0.525 N NaOH solution was added to neutralize, and absorbance was measured at 420 nm. Under this reaction condition, 1 ug of tyrosine for 1 minute The activity of protease was evaluated by setting the amount of enzyme to liberate 1 unint.
- GGT Gamma-glutamyltransferase, gamma-glutamyl transferase
- the activity of GGT was measured in a 50 mM phosphate buffer solution containing 0.01 ml of crude enzyme solution and 0.1 mM of rL-glutamyl-p-nitroaniline (p-NA-Glu, Sigma-Aldrich) ( pH 7.0) 0.09 ml was mixed and reacted at 40° C. for 30 minutes, followed by addition of 3.5 N acetic acid 0.01 ml to stop the reaction.
- the amount of free p-nitroaniline was measured at 410 nm.
- Enzyme activity was calculated by drawing a standard curve using p-nitroaniline as a standard solution.
- GGT enzyme activity 1 unit was calculated as the amount of enzyme that liberates 1 mole of p-nitroaniline from p-NA-Glu per minute to evaluate the GGT enzyme activity.
- Nattokinase activity is determined by mixing 350 ⁇ l of 50 mM borate buffer (pH 8.5), 100 ⁇ l of 1% fibrinogen solution, and 25 ⁇ l of 10 unint Thrombin solution, reacting at 37°C for 10 minutes, and then adding 25 ⁇ l of crude enzyme solution. The reaction was carried out at 37°C for 1 hour. 500 ul of 0.2 M TCA solution was added to the reaction solution to stop the reaction, and then left at 37° C. for 10 minutes. After centrifuging the reaction solution at 8,000 rpm for 20 minutes to recover the supernatant, the absorbance of the recovered supernatant was measured at 275 nm, and the enzyme activity was calculated by the following formula to evaluate the enzyme activity for lysis in blood.
- the protease activity was 78 U/ml
- the GGT activity was 3500 mU/ml
- the thrombolytic activity Nattokinase activity was 24 U/ml. appear.
- Enzyme activity evaluation B. polyfermenticus KMU01 Protease activity (U/ml) 78 GGT activity (mU/ml) 3500 Nattokinase activity (U/ml) 24
- Bacillus polyfermenticus Bacillus polyfermenticus ( Bacillus polyfermenticus ) KMU01 (Accession No.: KCTC 11751BP) strain is 61 peptidase (peptidase) genes, 23 protease (protease) genes, 8 glucosidase (glucosidase) gene, 6 lipase (lipase) gene, 2 GGT (r-glutamyl transpeptidase) gene, 2 cellulase (cellulase) gene, amylase (amylase) gene, and nattokinase (nattokinase) gene Confirmed.
- the degree of hydrolysis of the protein of the yaksoybean bioconversion powder prepared in Example 2 was evaluated. Take 2 mL of the hydrolyzate of each sample, put it in a test tube containing 2 mL of 20% (w/v) trichloroacetic acid (TCA), mix, centrifuge (3,000 ⁇ g, 10min), and centrifuge A certain amount of the supernatant was taken and the amount of protein was measured to calculate the degree of hydrolysis. As a result of the calculation, the degree of hydrolysis of the green soybean bioconversion powder was 53.8%.
- TCA trichloroacetic acid
- Functional amino acids in the medicinal bean bioconversion powder were analyzed using an automatic amino acid analyzer (Biochrom 30+). As shown in Table 3 below, it was found that the content of functional amino acids such as branched chain amino acids (BCAA) necessary for muscle growth and aromatic amino acids, which are precursor amino acids of neurotransmitters, increased.
- BCAA branched chain amino acids
- DPPH radical scavenging activity was analyzed to evaluate the antioxidant activity of the medicinal bean bioconversion powder.
- DPPH radical scavenging ability is a method of measuring the degree of reduction of DPPH radicals by reacting a stable free radical, 1.1-diphenyl-2-picryl hydrazyl (DPPH) with a certain sample solution, using a spectrophotometer. Sample 50 ul and 0.1 mM After mixing 50 ul of DPPH solution, it was left in a dark room at room temperature for 30 minutes, and absorbance was measured at 517 nm to calculate the degree of radical reduction compared to Control.
- DPPH radical scavenging ability is a method of measuring the degree of reduction of DPPH radicals by reacting a stable free radical, 1.1-diphenyl-2-picryl hydrazyl (DPPH) with a certain sample solution, using a spectrophotometer. Sample 50 ul and 0.1 mM After mixing 50 ul of DPPH solution, it
- Blank absorbance is measured by mixing 50 ul of water and 50 ul of 0.1mM DPPH solution, and control absorbance of each sample is measured by mixing 50 ul of sample and 95% ethanol. Ascorbic acid was used as a sample for the positive control group. As shown in FIG. 3 , a high DPPH radical scavenging activity of 74% was shown in the yaksoybean bioconversion powder compared to the control (yak soybean whole soymilk).
- Negative geotaxis literally expresses the action of moving up against gravity after dropping a fruit fly to the floor by applying a single impact to a glass tube or test tube containing fruit flies, and it is widely used in climbing assays.
- Parkinson-model Drosophila has negative geotaxis, but due to the deletion of the dj-1 gene, it shows a lower tendency of negative geotaxis than normal individuals. Deletion of the dj-1 gene promotes the apoptosis rate of dopamine, resulting in reduced mobility and reduced sleep time, such as symptoms of Parkinson's disease.
- the Parkinson's model Drosophila is a model in which the dj-1 gene is deleted, and the deletion of the dj-1 gene promotes the apoptosis rate of dopamine, thereby exhibiting phenomena such as reduced mobility and reduced sleep time, such as symptoms of Parkinson's disease. All fruit flies were cultured day/night at 12-hour intervals, maintaining the temperature at 25°C and humidity at 60%.
- Parkinson's disease fruit fly model (DJ-1B EX54 ) that consumed normal fruit fly rice (general diet)
- the climbing ability decreased to 25% at the 4th week, and the climbing ability decreased by 24% at the 5th week.
- Parkinson's model fruit fly (DJ-1B EX54 ) ingested with green soybean bioconversion powder (enzyme-treated whole soy milk) showed a climbing ability similar to that of wild fruit flies until 4 weeks, and at 5 weeks, when the climbing ability of wild fruit flies was 69%, Parkinson's It was confirmed that the model fruit fly (DJ-1B EX54 ) maintained the climbing ability of 51%, and through this result, it was confirmed that the medicinal bean bioconversion powder had the effect of improving behavioral disorders.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
효소 활성 평가 | B. polyfermenticus KMU01 |
Protease activity (U/ml) | 78 |
GGT activity (mU/ml) | 3500 |
Nattokinase activity (U/ml) | 24 |
구분 | 생물전환 조건 |
전두유 (mL) | 95 |
효소액 (mL) | 5 |
반응온도 (℃) | 37 |
반응시간 (hr) | 4 |
분류 | 아미노산 | 함량 (mg/L, mg/콩70g) | |
전두유(대조군) | 약콩생물전환 분말 | ||
방향족 | Phe | 8 | 65 |
Tyr | 5 | 28 | |
Trp | 14 | - | |
BCAA | Val | 8 | 72 |
Leu | 3 | 65 | |
Ile | 1 | 21 | |
기타 | GABA | 2 | 12 |
Glu | 17 | 9 | |
Cys | 5 | 14 | |
His | 8 | 75 | |
Pro | N/D | 51 | |
Lys | 3 | 79 | |
Arg | 110 | 111 |
Claims (10)
- 바실러스 폴리퍼멘티쿠스(Bacillus polyfermenticus) KMU01 (수탁번호: KCTC 11751BP) 균주, 이의 배양액, 이의 발효물, 또는 이들의 혼합물을 포함하는 생물전환용 조성물.
- 제1항에 있어서, 상기 배양액은 바실러스 폴리퍼멘티쿠스(Bacillus polyfermenticus) KMU01 (수탁번호: KCTC 11751BP) 균주를 배양한 인공 배지인 것을 특징으로 하는 생물전환용 조성물.
- 제1항에 있어서, 상기 발효물은 바실러스 폴리퍼멘티쿠스(Bacillus polyfermenticus) KMU01 (수탁번호: KCTC 11751BP) 균주를 이용하여 발효된 천연 배지인 것을 특징으로 하는 생물전환용 조성물.
- 제1항에 있어서, 상기 배양액 및 발효물은 프로테아제(protease), GGT(Gamma-glutamyltransferase, 감마-글루타밀 전이효소), 및 나토키나아제(Nattokinase)의 활성을 갖는 것을 특징으로 하는 생물전환용 조성물.
- 바실러스 폴리퍼멘티쿠스(Bacillus polyfermenticus) KMU01 (수탁번호: KCTC 11751BP) 균주, 이의 배양액, 이의 발효물, 또는 이들의 혼합물을 전두유에 처리하는 단계를 포함하는 약콩생물전환 분말 제조 방법.
- 제5항에 있어서, 상기 바실러스 폴리퍼멘티쿠스(Bacillus polyfermenticus) KMU01 (수탁번호: KCTC 11751BP) 균주, 이의 배양액, 이의 발효물, 또는 이들의 혼합물은 3%(v/v) 내지 7%(v/v) 농도로 처리하는 것을 특징으로 하는 약콩생물전환 분말 제조 방법.
- 제5항에 있어서, 상기 바실러스 폴리퍼멘티쿠스(Bacillus polyfermenticus) KMU01 (수탁번호: KCTC 11751BP) 균주, 이의 배양액, 이의 발효물, 또는 이들의 혼합물은 35℃ 내지 40℃에서 3 시간 내지 5 시간 동안 처리하는 것을 특징으로 하는 약콩생물전환 분말 제조 방법.
- 제5항에 있어서, 상기 약콩생물전환 분말은 항산화 활성을 나타내는 것을 특징으로 하는 약콩생물전환 분말 제조 방법.
- 바실러스 폴리퍼멘티쿠스(Bacillus polyfermenticus) KMU01 (수탁번호: KCTC 11751BP) 균주, 이의 배양액, 이의 발효물, 또는 이들의 혼합물을 이용하여 발효된 전두유를 유효성분으로 포함하는 행동장애의 예방 또는 치료용 약학 조성물.
- 바실러스 폴리퍼멘티쿠스(Bacillus polyfermenticus) KMU01 (수탁번호: KCTC 11751BP) 균주, 이의 배양액, 이의 발효물, 또는 이들의 혼합물을 이용하여 발효된 전두유를 유효성분으로 포함하는 행동장애의 예방 또는 개선용 건강기능 식품 조성물.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/027,621 US20230380469A1 (en) | 2020-09-21 | 2021-09-23 | Composition containing functional black soybean powder bioconverted by using bacillus enzymes as active ingredient, and use thereof |
CN202180078125.4A CN116615118A (zh) | 2020-09-21 | 2021-09-23 | 含有使用芽孢杆菌的酶进行生物转化的功能性黑豆粉作为活性成分的组合物及其用途 |
JP2023518313A JP2023542043A (ja) | 2020-09-21 | 2021-09-23 | バチルス酵素群を利用した生物転換された機能性薬豆粉末を有効成分として含む組成物及びその用途 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200121669 | 2020-09-21 | ||
KR10-2020-0121669 | 2020-09-21 | ||
KR1020210124767A KR20220039616A (ko) | 2020-09-21 | 2021-09-17 | 바실러스 효소군 이용 생물전환된 기능성 약콩분말을 유효성분으로 포함하는 조성물 및 이의 용도 |
KR10-2021-0124767 | 2021-09-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022060204A1 true WO2022060204A1 (ko) | 2022-03-24 |
Family
ID=80777218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/012972 WO2022060204A1 (ko) | 2020-09-21 | 2021-09-23 | 바실러스 효소군 이용 생물전환된 기능성 약콩분말을 유효성분으로 포함하는 조성물 및 이의 용도 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20230380469A1 (ko) |
JP (1) | JP2023542043A (ko) |
WO (1) | WO2022060204A1 (ko) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100811615B1 (ko) * | 2006-11-17 | 2008-03-11 | 건국대학교 산학협력단 | 바실러스 폴리퍼멘티쿠스 균주의 에탄올 추출물을 이용한된장의 갈변 억제방법 |
KR20130095127A (ko) * | 2012-02-17 | 2013-08-27 | 연세대학교 원주산학협력단 | 감마 글루타밀트랜스펩티데이스 및 피브린 분해효소의 활성이 높은 바실러스 아밀로리큐파시엔스 kc41 및 이를 이용하여 제조한 청국장 |
KR20200001451A (ko) * | 2018-06-26 | 2020-01-06 | 국민대학교산학협력단 | 내염성 감마-글루타밀 트랜스펩티데이즈를 생산하는 신규한 호염성 바실러스 폴리퍼멘티쿠스 균주 |
-
2021
- 2021-09-23 US US18/027,621 patent/US20230380469A1/en active Pending
- 2021-09-23 JP JP2023518313A patent/JP2023542043A/ja active Pending
- 2021-09-23 WO PCT/KR2021/012972 patent/WO2022060204A1/ko active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100811615B1 (ko) * | 2006-11-17 | 2008-03-11 | 건국대학교 산학협력단 | 바실러스 폴리퍼멘티쿠스 균주의 에탄올 추출물을 이용한된장의 갈변 억제방법 |
KR20130095127A (ko) * | 2012-02-17 | 2013-08-27 | 연세대학교 원주산학협력단 | 감마 글루타밀트랜스펩티데이스 및 피브린 분해효소의 활성이 높은 바실러스 아밀로리큐파시엔스 kc41 및 이를 이용하여 제조한 청국장 |
KR20200001451A (ko) * | 2018-06-26 | 2020-01-06 | 국민대학교산학협력단 | 내염성 감마-글루타밀 트랜스펩티데이즈를 생산하는 신규한 호염성 바실러스 폴리퍼멘티쿠스 균주 |
Non-Patent Citations (2)
Title |
---|
AE-YOUNG MO ; BORA KWON ; SERALATHAN KAMALA-KANNAN ; KUI-JAE LEE ; BYUNG-TAEK OH ; DAE-HYUK KIM ; MOON-SIK YANG ; JIN-HYUNG KIM ; : "Isolation and characterization of Bacillus polyfermenticus isolated from Meju, Korean soybean fermentation starter", WORLD JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, vol. 26, no. 6, 16 December 2009 (2009-12-16), Do , pages 1099 - 1105, XP019832705, ISSN: 1573-0972 * |
COGLIATI, SEBASTIÁN , CLEMENTI, VICTORIA , FRANCISCO, MARCOS , CRESPO, CIRA , ARGAÑARAZ, FEDERICO , GRAU, ROBERTO: "Bacillus Subtilis Delays Neurodegeneration and Behavioral Impairment in the Alzheimer’s Disease Model Caenorhabditis Elegans. ", JOURNAL OF ALZHEIMER`S DISEASE, IOS PRESS, NL, vol. 73, no. 3, 4 February 2020 (2020-02-04), NL , pages 1035 - 1052, XP009535060, ISSN: 1387-2877, DOI: 10.3233/JAD-190837 * |
Also Published As
Publication number | Publication date |
---|---|
JP2023542043A (ja) | 2023-10-04 |
US20230380469A1 (en) | 2023-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018186710A1 (ko) | 최종당화산물 저감 활성을 갖는 신규한 균주 및 이의 용도 | |
US11633439B2 (en) | Lactobacillus crispatus KBL693 strain and use thereof | |
WO2020196992A1 (ko) | 비형광성 최종당화산물 억제용 조성물 및 이의 용도 | |
WO2022075660A1 (ko) | 알파-글루코시다아제 저해제를 생산하는 신규한 바실러스 코아귤란스 cc 균주 | |
KR100734975B1 (ko) | 1-데옥시노지리마이신을 생산하는 바실러스 서브틸리스s10 균주 및 이를 유효성분으로 함유하는 조성물 | |
WO2021251575A1 (ko) | 신규한 페디오코커스 펜토사세우스 균주 및 이의 유청 발효물을 포함하는 비만 또는 지방간 질환의 예방 또는 개선용 식품 조성물 | |
WO2018043874A1 (ko) | 지방 분해능을 갖는 균주를 포함하는 탈모 방지 또는 발모 촉진용 조성물 | |
WO2021085854A1 (ko) | 글루타치온을 생산하는 효모 균주 및 이를 이용한 글루타치온 생산방법 | |
WO2021230581A1 (ko) | 신규한 아커만시아 뮤시니필라 ak32 균주의 발견 및 장 손상의 예방 또는 치료를 위한 응용 | |
WO2022060204A1 (ko) | 바실러스 효소군 이용 생물전환된 기능성 약콩분말을 유효성분으로 포함하는 조성물 및 이의 용도 | |
WO2022060200A2 (ko) | 바실러스균 유래 효소군 이용 생물전환된 기능성 약콩분말의 생물전환 공정개발 및 이의 용도 | |
KR100889300B1 (ko) | 바실러스 서브틸리스 kk71 균주 및 이의 배양액을유효성분으로 함유하는 혈당강하용 조성물 | |
WO2024071624A1 (ko) | 키위 발효물을 포함하는 알코올성 간손상 예방 또는 개선용 조성물 | |
WO2022060199A1 (ko) | 숙성 육류에서 분리된 신규 유산균 및 이의 용도 | |
WO2023014054A1 (ko) | 블라우티아 속 균주, 류코노스톡 속 균주 또는 루미노코쿠스 속 균주 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 | |
KR102653994B1 (ko) | 숙성 육류에서 분리된 신규 유산균 및 이의 용도 | |
KR20220039616A (ko) | 바실러스 효소군 이용 생물전환된 기능성 약콩분말을 유효성분으로 포함하는 조성물 및 이의 용도 | |
WO2021242056A1 (ko) | 비피도박테리움 속 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 | |
WO2021242057A1 (ko) | 락토바실러스 속 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 | |
WO2021071159A1 (ko) | 서목태의 효모 발효물을 포함하는 혈당강하, 혈압강하 또는 항산화용 조성물 및 상기 조성물의 제조 방법 | |
KR20220039618A (ko) | 바실러스균 유래 효소군 이용 생물전환된 기능성 약콩분말의 생물전환 공정개발 및 이의 용도 | |
KR20220005717A (ko) | 글루텐 분해활성을 갖는 바실러스 아밀로리쿼파시엔스 플란타럼 아종 kfri-g001 및 이의 용도 | |
WO2020091504A1 (ko) | 혈전용해효소 나토키나아제를 생산하는 신규한 호염성 바실러스 아밀로리퀴파션스 kmus1 | |
WO2023043218A1 (ko) | 바실러스 서브틸리스 낫또 배양균체 추출물을 포함하는 기억력 개선용 조성물 | |
CN116615118A (zh) | 含有使用芽孢杆菌的酶进行生物转化的功能性黑豆粉作为活性成分的组合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21869826 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2023518313 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18027621 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180078125.4 Country of ref document: CN |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 03.08.2023) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21869826 Country of ref document: EP Kind code of ref document: A1 |